共 50 条
- [1] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1073 - 1080
- [4] Urinary excretion kinetics of [177Lu]Lu-PSMA-617 [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 3572 - 3575
- [7] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer [J]. LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
- [9] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3269 - 3276
- [10] PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 1200 - 1210